Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
HHS Secretary Alex Azar says that reshaping Administration’s upcoming proposed rule would drive Medicare Part B drug prices even lower than previously projected. As Part B drug costs are being blamed for higher premiums, the policy revisions are at OMB, but plan would reemerge as "a notice of proposed rulemaking if that comes out,” Azar said.
Tufts researchers report restrictions are more common for orphan drugs indicated for diseases with higher prevalence and that are more expensive.
“We’re out of time for ideas," Domestic Policy Council Director Joe Grogan says. Trump administration is pushing hard to get the Senate drug pricing bill through Congress quickly and score a major victory for the President.
Political focus of drug pricing debate has shifted away from pharmacy benefit managers, CVS Health’s Merlo suggests.
Price inflation rebates are the linchpin of the legislation’s Democratic support, Sen. Chuck Grassley, R-IA, argues. But to many Republicans, they sound too much like price controls.
Former drug pricing advisor John O’Brien discusses next steps for Administration policies around importation and international reference pricing during a speech to the Academy of Managed Care Pharmacy.